- Company
- Market for Pulmicort and Pulmican soars 2.6 times in 2 years
- by Chon, Seung-Hyun Feb 14, 2024 05:40am
- Last year, the prescription market for asthma medications containing the ‘budesonide’ ingredient expanded to its largest size ever. There have been significant demands for the treatment due to the circumstances surrounding the pandemic and endemic. At the end of last year, the drug pricing increase led to manufacturing and the prescription mar
- Company
- Unstoppable sales growth of Entresto
- by Kim, Jin-Gu Feb 13, 2024 06:18am
- Novartis Korea’s Entresto, a heart failure treatment, repeatedly shows significant growth. Entresto has consistently achieved over 30% growth in sales each year since its release in October 2017, having passed six years. Since its release, Entresto has undergone five price reductions to suppress the steep increase in prescription sales
- Company
- ‘Biobetter Nexviazyme is a better treatment option'
- by Eo, Yun-Ho Feb 13, 2024 05:51am
- There are times when a single treatment has a significant impact on the overall management of the disease. This is especially true for rare and incurable diseases. In the field of metabolic diseases, a paradigm shift occurred when researchers found that certain rare patients lacked a single enzyme, which led to the development of therapie
- Company
- Yuhan Chemical completes FDA and ANVISA inspections
- by Nho, Byung Chul Feb 7, 2024 05:59am
- Yuhan Chemical (CEO & President: Sang-Hun Seo) has confirmed its global-scale capacity for manufacturing and quality management systems. Yuhan Chemical announced on the 5th that the company has successfully completed the inspections of the United States Food and Drug Associations (FDA) and the Brazilian Health Surveillance Agency (ANVI
- Company
- Bayer partners with Chong Kun Dang to sell Kerendia
- by Nho, Byung Chul Feb 7, 2024 05:59am
- An upturn is expected in the KRW 20 billion markets for chronic kidney disease treatments, with Bayer and Chong Kun Dang joining forces to establish a joint sales front for its chronic kidney disease treatment, Kerendia Tab, According to industry sources, Bayer and Chong Kun Dang signed a joint sales agreement for Kerendia Tab today (Fe
- Company
- KRW 40 bil JAKi market is in a fierce three-way race
- by Kim, Jin-Gu Feb 7, 2024 05:59am
- The competition is intensifying leadership in the Janus kinase (JAK) inhibitor market, an oral autoimmune disease treatment, in Korea. Lilly's Olumiant (baricitinib) became the market leader in Q2 last year, as sales of the longtime leader Pfizer's Xeljanz (tofacitinib) faltered. Then, in just 2 quarters, AbbVie's Rinvoq (upadacitinib)
- Company
- Colorectal cancer drug Fruzaqla gets Orphan Drug Designation
- by Eo, Yun-Ho Feb 7, 2024 05:59am
- The new colorectal drug ‘Fruzaqla’ received the Orphan Drug Designation in Korea. On the 1st, the Ministry of Food and Drug Safety (MFDS) announced this decision through the Orphan Drug Designation posting. Fruzaqla is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously t
- Company
- Oral ulcerative colitis drug Zeposia is actively prescribed
- by Eo, Yun-Ho Feb 6, 2024 06:10am
- Prescription of new oral ulcerative colitis drug Zeposia is being actively promoted in general hospitals in Korea. According to industry sources, BMS Korea’s ‘Zeposia Cap (ozanimod)’ has passed drug committee (DC) reviews of major tertiary hospitals in Korea including Samsung Medical Center, Seoul National University Hospital, Seoul A
- Company
- Growth hormone Ngenla can be prescribed in general hospitals
- by Eo, Yun-Ho Feb 5, 2024 05:54am
- The growth hormone ‘Ngenla’ can now be prescribed in general hospitals in Korea. According to industry sources, Pfizer Korea’s once-weekly growth hormone Ngenla (somatrogon) has passed the drug committee (DC) reviews of tertiary hospitals including Seoul Asan Medical Center and Sinchon Severance Hospital, as well as medical instituti
- Company
- Enhertu passes the DREC review in KOR
- by Eo, Yun-Ho Feb 5, 2024 05:54am
- ‘Enhertu,’ which had faced difficulties in securing insurance reimbursement listing due to its exceptional effectiveness, has finally received approval from the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA). This approval comes eight months after Enhertu passed the review by t
